Korea University Medical Center Expands Collaboration with Johns Hopkins and TMC

Connecting Domestic Bio and Medical Companies with U.S. Research, Clinical, and Investment Networks
Exploring Strategies from FDA Approval and Market Entry to Joint Research and Commercialization

Korea University Medical Center is expanding collaboration with U.S. medical innovation organizations such as Johns Hopkins Technology Ventures (JHTV) and Texas Medical Center (TMC) to support the entry of domestic bio and medical technologies into the U.S. market.

On September 22, Korea University Medical Center announced that it held the '2026 Korea-JHTV Bio Partnering Day' and the 'Korea-TMC Bio Partnering Day' at Korea University Mediscience Park on the 4th and 17th, respectively. These events were organized to connect domestic bio and medical companies with U.S. research, clinical, and investment networks.

A group photo was taken at the ‘Korea-JHTV Bio Partnering Day’ held on the 4th. Korea University Medical Center

At the JHTV event, the technology commercialization system of Johns Hopkins and examples of collaboration with Korean companies were introduced. The discussions focused on organoid-based drug response analysis, medical imaging and artificial intelligence (AI), and liquid biopsy, with a particular emphasis on research and clinical validation in the U.S. and joint development strategies.

The TMC event primarily addressed strategies for entering the U.S. market. David McDonough, Entrepreneur-in-Residence at TMC Innovation Factory, explained that market demand, potential for insurance reimbursement, intellectual property, local corporate structure, and U.S. Food and Drug Administration (FDA) approval strategies should be thoroughly reviewed in advance.

The TMC side also introduced Houston's medical and life science cluster, as well as its startup support system. Programs focused on supporting startups in therapeutics and medical devices, venture funds, and initiatives aiding overseas companies in entering the U.S. market—centered around the TMC Innovation Factory—were presented.

Individual partnering sessions between domestic companies and overseas organizations also took place. Four companies—Aimmune Link, Genopsy, Elixir Pharmatech, and Arale Research Institute—participated in the JHTV event, while five companies—Aimmune Link, Oncocross, CialBio, Checkmate Therapeutics, and Genopsy—joined the TMC event. These companies showcased their technologies and development status and discussed collaborative research, clinical cooperation, and commercialization strategies.

Korea University Medical Center plans to expand these events beyond one-time exchanges into a cooperation network supporting the overseas advancement of domestic medical technologies. The institution aims to broaden the scope of collaboration to include foreign research, medical, and investment organizations to support the research, clinical validation, and commercialization of promising domestic medical technologies.

Hakjun Kim, Director of the Medical Research Institute at Korea University, stated, "For excellent research results to be put to actual use in clinical practice and lead to commercialization, various specialized institutions in research, clinical, investment, and commercialization must engage from the early stages of technology development. Korea University Medical Center will strengthen its role as a hub connecting domestic research institutes and companies with overseas innovation organizations, supporting tangible joint research and successful global commercialization outcomes."

This content was produced with the assistance of AI translation services.